MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-23-2026
AcelRx Pharmaceuticals ROE Ratio 2011-2026 | ACRX
Annual ROE Ratio AcelRx Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -83.89 | -162.53 | -130.43 | 218.92 | 97.79 | 72.43 | 128.54 | -1108.61 | 141.08 | 808.64 | -73.68 | -71.49 | -32.02 | -98.57 | -115.07 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 808.64 | -1108.61 | -27.26 |
Quarterly ROE Ratio AcelRx Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -156.87 | -168.52 | -145.93 | -89.05 | -96.46 | -69.09 | -80.98 | -106.6 | -131.4 | -148.78 | 106.38 | 211.08 | 230.54 | 274.8 | 88.97 | 79.63 | 95.65 | 92.2 | 76.68 | 56.43 | 91.26 | 105.98 | 124.09 | 128.54 | -201.55 | -525.21 | -803.03 | -1108.61 | -786.26 | -457.69 | -174.07 | 141.08 | 295.42 | 473.42 | 645.48 | 808.64 | 595.38 | 397.04 | 162.35 | -73.68 | -71.45 | -85.32 | -81.12 | -71.49 | -17.58 | -34.04 | -35.22 | -32.02 | -87.4 | -97.73 | -95.14 | -98.57 | -103.97 | -111.59 | -117.6 | -115.07 | -32.98 | -27.27 | -18.34 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 808.64 | -1108.61 | -23.33 |
ROE Ratio of other stocks in the Drug manufacturers industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agile Therapeutics
AGRX
|
88.64 | - | 10.11 % | $ 58.2 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
3276.74 | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
431.6 | - | - | $ 754 M | USA |
 |
Assertio Holdings
ASRT
|
-32.33 | $ 18.02 | - | $ 115 M | USA |
 |
Catalent
CTLT
|
-28.94 | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-186.86 | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
-43.6 | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
1589.72 | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
15.26 | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
37.13 | - | - | $ 28.9 M |  Irlanda |
 |
Avadel Pharmaceuticals plc
AVDL
|
-66.13 | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
302.08 | - | - | $ 36.6 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-8.33 | $ 3.09 | -0.64 % | $ 43.4 M | USA |
 |
Cronos Group
CRON
|
-4.28 | $ 2.58 | 1.18 % | $ 1.34 B |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-50.54 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-98.17 | - | 2.45 % | $ 38.1 M | Canada |
 |
Bausch Health Companies
BHC
|
57.93 | $ 5.6 | 3.9 % | $ 2.04 B | Canada |
 |
Harrow Health
HROW
|
-9.8 | $ 35.93 | -3.65 % | $ 1.32 B | USA |
 |
Aurora Cannabis
ACB
|
-154.42 | $ 3.43 | -1.44 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
-122.76 | $ 1.05 | -3.67 % | $ 113 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
-34.11 | - | - | $ 193 M | Canada |
 |
Jupiter Wellness
JUPW
|
-194.84 | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
-45.46 | $ 1.4 | -2.78 % | $ 402 M | Canada |
 |
Lannett Company
LCI
|
92.26 | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
223.5 | $ 4.27 | 0.71 % | $ 275 M | USA |
 |
Emergent BioSolutions
EBS
|
-117.13 | $ 7.96 | -5.8 % | $ 408 M | USA |
 |
Organogenesis Holdings
ORGO
|
0.33 | $ 2.38 | 3.93 % | $ 313 M | USA |
 |
Pacira BioSciences
PCRX
|
-12.79 | $ 23.79 | -0.13 % | $ 1.1 B | USA |
 |
PetIQ
PETQ
|
0.96 | - | 1.64 % | $ 400 M | USA |
 |
Sundial Growers
SNDL
|
-88.87 | $ 1.42 | 2.9 % | $ 3.37 M | Canada |
 |
ProPhase Labs
PRPH
|
29.02 | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
27.81 | - | - | $ 1.42 B | USA |
 |
Relmada Therapeutics
RLMD
|
-66.33 | $ 7.29 | -4.2 % | $ 288 M | USA |
 |
Recro Pharma
REPH
|
-22.63 | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
40.97 | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-17.44 | $ 1.0 | 0.81 % | $ 49.9 M | USA |
 |
PLx Pharma
PLXP
|
-129.32 | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-96.84 | $ 8.02 | -0.99 % | $ 702 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-78.37 | $ 2.28 | -5.39 % | $ 2.83 M | USA |
 |
Tilray
TLRY
|
-43.81 | $ 6.57 | -2.23 % | $ 4.06 B | Canada |
 |
Veru
VERU
|
-116.97 | $ 2.38 | -2.06 % | $ 321 M | USA |
 |
Viatris
VTRS
|
0.27 | $ 13.47 | -1.03 % | $ 16.2 B | USA |
 |
cbdMD
YCBD
|
-7.78 | $ 0.68 | 4.01 % | $ 2.93 M | USA |
 |
Zomedica Corp.
ZOM
|
-70.94 | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-75.79 | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-14.37 | $ 0.91 | -2.17 % | $ 32.7 M | USA |
 |
Tricida
TCDA
|
-80993.58 | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-14.02 | $ 0.63 | -3.82 % | $ 2.7 M |  China |
 |
TherapeuticsMD
TXMD
|
-2.12 | $ 2.07 | 0.98 % | $ 23.9 M | USA |